Read by QxMD icon Read

cardio- oncology

Timothy M Markman, Maurie Markman
Traditional chemotherapeutic agents and newer targeted therapies for cancer have the potential to cause cardiovascular toxicities. These toxicities can result in arrhythmias, heart failure, vascular toxicity, and even death. It is important for oncologists and cardiologists to understand the basic diagnostic and management strategies to employ when these toxicities occur. While anti-neoplastic therapy occasionally must be discontinued in this setting, it can often be maintained with caution and careful monitoring...
2019: F1000Research
Allison Padegimas, Suparna Clasen, Bonnie Ky
Breast cancer is the most common malignancy affecting females, with over 260,000 new cases annually and over 3.1 million survivors in the United States alone. Exposure to potentially cardiotoxic therapies, including anthracyclines, trastuzumab, and radiation therapy, coupled with host factors, place patients at increased risk for the development of cardiovascular disease (CVD) compared to non-cancer controls. Overall survival outcomes are significantly worse in patients who develop CVD, and in certain breast cancer populations, cardiovascular death exceeds the risk of cancer death in the long-term...
January 29, 2019: Trends in Cardiovascular Medicine
Oliver J Müller, Martina E Spehlmann, Norbert Frey
Immune checkpoint inhibitors (ICIs) have started revolutionizing the treatment of numerous advanced oncological diseases by restoring immune resistance against cancer cells. ICI-associated cardiac adverse effects are rare, but severe. About 50% of cardiac complications comprise myocarditis with variable clinical presentation and a high rate of fatality. The pathomechanism is incompletely understood and may involve preexisting autoimmunity such as autoantibodies or common epitopes shared by cardiomyocytes and tumor cells...
December 2018: Journal of Thoracic Disease
Tienush Rassaf, Matthias Totzeck
Cardio-oncology has emerged as best option for many patients with cardiovascular complications related to cancer and cancer therapy. Classical chemotherapy, targeted and immune therapies as wells as radiotherapy challenge the cardiovascular system at multiple levels, including increased rates of e.g., hypertension, coronary artery disease, cardiomyopathy, arrhythmia, and thrombosis. The cardiologist working within the cardio-oncology team is confronted with a broad spectrum of therapies and combination protocols...
December 2018: Journal of Thoracic Disease
Amir Abbas Mahabadi, Christoph Rischpler
Cancer therapy may lead to cardiovascular complications and can promote each aspect of cardiac disease manifestation, such as vascular disease including coronary heart disease, myocardial diseases including heart failure, structural heart diseases including valvular heart diseases, and rhythm disorders. All potential complications of cancer therapy onto the cardiovascular system require imaging for diagnostic workup as well as monitoring of therapy. Transthoracic echocardiography (TTE) is the most frequently used tool for assessment of cardiac function during or after cancer therapy in daily clinical routine...
December 2018: Journal of Thoracic Disease
Tienush Rassaf
No abstract text is available yet for this article.
December 2018: Journal of Thoracic Disease
Roberto Carnevale, Gaetano Lanzetta, Giuseppe Biondi-Zoccai, Giacomo Frati
No abstract text is available yet for this article.
January 16, 2019: International Journal of Cardiology
Emily A Pinheiro, K Ashley Fetterman, Paul W Burridge
The genomic predisposition to oncology-drug-induced cardiovascular toxicity has been postulated for many decades. Only recently has it become possible to experimentally validate this hypothesis via the use of patient-specific human induced pluripotent stem cells (hiPSCs) and suitably powered genome-wide association studies (GWAS). Identifying the individual single nucleotide polymorphisms (SNPs) responsible for the susceptibility to toxicity from a specific drug is a daunting task as this precludes the use of one of the most powerful tools in genomics: comparing phenotypes to close relatives, as these are highly unlikely to have been treated with the same drug...
January 24, 2019: Cardiovascular Research
Matthias Totzeck, Martin Schuler, Martin Stuschke, Gerd Heusch, Tienush Rassaf
Current therapy of advanced cancers is based on several modalities including radiotherapy, cytotoxic chemotherapy, molecularly targeted inhibitors and antibodies targeting immune checkpoints. All of those these modalities can negatively impact the cardiovascular system, and there is considerable experience in relation to radiotherapy and chemotherapy. In contrast, the knowledge base on cardiovascular toxicities of novel agents targeting signal transduction pathways and immune regulation is quite limited. In particular, potential late effects are of concern as cardiovascular pathology can negatively impact quality of life and prognosis in cancer survivors, particularly when additional cardiovascular risk factors are present...
January 11, 2019: International Journal of Cardiology
Alexandra Danielle Dreyfuss, Paco Bravo, Constantinos Koumenis, Bonnie Ky
Modern oncologic therapies and care have resulted in a growing population of cancer survivors with comorbid, chronic health conditions. As an example, many survivors suffer from an increased risk of cardiovascular complications secondary to cardiotoxic systemic and radiation therapies. In response, the field of cardio-oncology has emerged as an integral component of oncologic patient care, committed to the early diagnosis and treatment of adverse cardiac events. However, as current clinical management of cancer therapy-related cardiovascular disease (CVD) remains limited by a lack of phenotypic data, implementation of precision medicine approaches has become a focal point for deep phenotyping strategies...
January 17, 2019: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Margot K Davis, Sean A Virani
No abstract text is available yet for this article.
December 26, 2018: Canadian Journal of Cardiology
Evangelos Oikonomou, Μaria Anastasiou, Gerasimos Siasos, Emmanuel Androulakis, Amanda Psyrri, Konstantinos Toutouzas, Dimitris Tousoulis
BACKGROUND: Chemotherapy regimens have improved prognosis and mortality of patients with malignant diseases. The development of therapies however has widened the cardiotoxic spectrum and the cardiac related effects of antineoplastic drugs. METHODS: A review of the literature under the search terms Anthracyclines; oncology; cardiotoxicity, cardio-oncology; chemotherapy; heart failure was used for the identification of the most relevant articles. RESULTS: Considerable variability exists in patients' characteristics, in mechanisms involved in cardiomyopathy progression and in its physical history, as well as in modalities used to screen myocardial competence...
January 10, 2019: Current Pharmaceutical Design
Angel López-Candales
No abstract text is available yet for this article.
January 11, 2019: Postgraduate Medicine
Vasiliki Katsi, Nikolaos Magkas, Georgios Georgiopoulos, Eleni Athanasiadi, Agostino Virdis, Stefano Masi, Panagiotis Kliridis, Amalia Hatziyanni, Costas Tsioufis, Dimitrios Tousoulis
BACKGROUND: Cardio-oncology aims to mitigate adverse cardiovascular manifestations in cancer survivors, but treatment-induced hypertension or aggravated hypertension has received less attention in these high cardiovascular risk patients. METHODS: In this systematic review, we searched literature for contemporary data on the prevalence, pathophysiologic mechanisms, treatment implications and preventive strategies of hypertension in patients under antineoplastic therapy...
January 7, 2019: Journal of Hypertension
Lars Michel, Tienush Rassaf
Cancer and cardiovascular diseases are the main causes for morbidity and mortality in modern society. In the United States of America (USA), over 1.7 million new cancer cases will presumably be observed in 2018. Progress in cancer treatment has greatly improved survival and it is estimated that 15.5 million cancer survivors currently live in the USA. The number of cancer survivors is expected to increase by 68% until 2040. Moreover, the portion of cancer survivors at the age of 65 years or older will increase from 62% to approximately 73% in 2040 which in turn enhances comorbidities in cancer survivors...
January 3, 2019: European Journal of Medical Research
Caroline Austin-Mattison
Patients have been surviving cancer diagnoses at a steadily increasing rate over the past few decades. Despite the encouraging decline in cancer morbidity, the cardiovascular effect of some chemotherapy medications is concerning. Moreover, even though there is extensive knowledge of the pathophysiology and increased risk of cardiotoxicity, there is a lack of specific guidelines and adequate cardio-oncology programs focused on reducing cardiovascular risks or disease in patients undergoing cancer treatment. The high incidence of both cardiovascular disease (CVD) and cancer warrants the collaboration of oncology and cardiology providers to screen and promptly treat CVD, and thereby provide an opportunity to improve cancer patients' quality of life both during treatment and extended through cancer survivorship...
March 2018: Journal of the Advanced Practitioner in Oncology
Jessica Shank Coviello
Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary and secondary risk strategies through surveillance as well as interventions to reduce cardiovascular risk (CVR), prevent cardiotoxicities, and manage the side effects that may occur. Rather than discuss in detail the cardiotoxicities of specific therapies or radiation, this review article will explore the interplay of cancer, cancer treatment, and CVR...
March 2018: Journal of the Advanced Practitioner in Oncology
Jessica Shank Coviello
No abstract text is available yet for this article.
March 2018: Journal of the Advanced Practitioner in Oncology
Markus S Anker, Alessia Lena, Sara Hadzibegovic, Yury Belenkov, Jutta Bergler-Klein, Rudolf A de Boer, Alain Cohen-Solal, Dimitrios Farmakis, Stephan von Haehling, Teresa López-Fernández, Radek Pudil, Thomas Suter, Carlo G Tocchetti, Alexander R Lyon
During the 'Heart Failure and World Congress on Acute Heart Failure 2018', many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the 'Heart Failure and World Congress on Acute Heart Failure 2018'...
December 2018: ESC Heart Failure
Alicia Armour
No abstract text is available yet for this article.
December 2018: Journal of the American Society of Echocardiography
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"